Allison Betof Warner: Relativity-048 presented by Paolo A. Ascierto at ASCO24

Allison Betof Warner, Director of Melanoma Medical Oncology and Solid Tumor Cellular Therapy at Stanford Cancer Institute, recently posted on X:

“We’ve been waiting for this one!!

RELATIVITY-048 (ipilimumab 1Q8wi and nivolumab and relatimab) presented by Paolo A. Ascierto.

ORR 52% by BICR. Clinical benefit rate 76%. 50% discontinuation due to toxicity.

Responses in poor prognosis disease.

7/14 with liver metastasis and 2/3 with brain metastasis responded. More to come on brian mets with this combination!

Rate of G3/4 TRAE is a 39%…actually significantly better than full dose ipilimumab and nivolumab.”

Source: Allison Betof Warner/X